Erste Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-25,200
| Closed | -$1.48M | – | 586 |
|
|
2023
Q4 | $1.48M | Hold |
25,200
| – | – | 0.02% | 333 |
|
|
2023
Q3 | $1.14M | Hold |
25,200
| – | – | 0.02% | 333 |
|
|
2023
Q2 | $919K | Hold |
25,200
| – | – | 0.02% | 370 |
|
|
2023
Q1 | $925K | Hold |
25,200
| – | – | 0.02% | 372 |
|
|
2022
Q4 | $1.08M | Hold |
25,200
| – | – | 0.02% | 350 |
|
|
2022
Q3 | $1.76M | Hold |
25,200
| – | – | 0.04% | 293 |
|
|
2022
Q2 | $1.69M | Hold |
25,200
| – | – | 0.04% | 298 |
|
|
2022
Q1 | $2.1M | Hold |
25,200
| – | – | 0.04% | 288 |
|
|
2021
Q4 | $3.63M | Hold |
25,200
| – | – | 0.07% | 244 |
|
|
2021
Q3 | $4.39M | Buy |
25,200
+12,000
| +91% | +$1.93M | 0.09% | 212 |
|
|
2021
Q2 | $2.14M | Hold |
13,200
| – | – | 0.04% | 276 |
|
|
2021
Q1 | $2.19M | Hold |
13,200
| – | – | 0.05% | 258 |
|
|
2020
Q4 | $2.92M | Sell |
13,200
-100
| -0.8% | -$21.6K | 0.08% | 231 |
|
|
2020
Q3 | $2.21M | Buy |
13,300
+2,300
| +21% | +$315K | 0.08% | 234 |
|
|
2020
Q2 | $1.26M | Hold |
11,000
| – | – | 0.05% | 276 |
|
|
2020
Q1 | $905K | Hold |
11,000
| – | – | 0.05% | 265 |
|
|
2019
Q4 | $1.41M | Hold |
11,000
| – | – | 0.06% | 242 |
|
|
2019
Q3 | $929K | Hold |
11,000
| – | – | 0.05% | 270 |
|
|
2019
Q2 | $1.15M | Hold |
11,000
| – | – | 0.06% | 238 |
|
|
2019
Q1 | $812K | Buy |
+11,000
| New | +$748K | 0.05% | 265 |
|
Other funds holding MRTX
Erste Asset Management's MRTX Position: Q1 2024 in Review
Erste Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 25,200 shares — an estimated $1.48M sold.
Erste Asset Management first reported a position in MRTX in Q1 2019 and held it in 20 quarters. The position peaked at $4.39M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Erste Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Erste Asset Management sold 25,200 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.48M.
- Erste Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
- Erste Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.39M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Erste Asset Management's 13F filing for Q1 2024, filed 26 Nov 2024.